Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1992 May;76(1):140–145.

Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59.

M G Wing 1, J Zajicek 1, D J Seilly 1, D A Compston 1, P J Lachmann 1
PMCID: PMC1421748  PMID: 1378423

Abstract

Rat oligodendrocytes, which activate the classical pathway of complement in the absence of antibody, are highly sensitive in a reactive lysis assay using human C5b6 and EDTA serum. Oligodendrocytes may be relatively deficient in glycolipid-linked complement regulatory protein(s), since digestion with phosphatidylinositol-specific phospholipase C (PI-PLC) failed to increase their sensitivity to serum, whereas complement-insensitive astrocytes, when treated with PI-PLC, became strikingly sensitive. To test the hypothesis that oligodendrocytes lack terminal complement regulatory molecule(s), human erythrocyte CD59, a recently described complement regulatory protein, was purified to homogeneity. The biological activity of the preparation was confirmed by reincorporating the protein into guinea-pig erythrocytes through its glycolipid anchor, which resulted in dose-dependent protection against human C5b6 and EDTA serum. Incorporation of 10(5) molecules of human CD59 into rat oligodendrocytes resulted in good protection against homologous human complement (76%), and significant protection against rat complement homologous to the cell (36%). Protection could be reversed using an antibody to CD59.

Full text

PDF
140

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bottenstein J. E., Sato G. H. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci U S A. 1979 Jan;76(1):514–517. doi: 10.1073/pnas.76.1.514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Compston A., Scolding N., Wren D., Noble M. The pathogenesis of demyelinating disease: insights from cell biology. Trends Neurosci. 1991 May;14(5):175–182. doi: 10.1016/0166-2236(91)90099-g. [DOI] [PubMed] [Google Scholar]
  3. Compston D. A., Morgan B. P., Campbell A. K., Wilkins P., Cole G., Thomas N. D., Jasani B. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol. 1989 Jul-Aug;15(4):307–316. doi: 10.1111/j.1365-2990.1989.tb01231.x. [DOI] [PubMed] [Google Scholar]
  4. Cyong J. C., Witkin S. S., Rieger B., Barbarese E., Good R. A., Day N. K. Antibody-independent complement activation by myelin via the classical complement pathway. J Exp Med. 1982 Feb 1;155(2):587–598. doi: 10.1084/jem.155.2.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989 Sep 1;170(3):637–654. doi: 10.1084/jem.170.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davitz M. A., Low M. G., Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med. 1986 May 1;163(5):1150–1161. doi: 10.1084/jem.163.5.1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gay D., Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain. 1991 Feb;114(Pt 1B):557–572. doi: 10.1093/brain/114.1.557. [DOI] [PubMed] [Google Scholar]
  8. Hänsch G. M., Weller P. F., Nicholson-Weller A. Release of C8 binding protein (C8bp) from the cell membrane by phosphatidylinositol-specific phospholipase C. Blood. 1988 Sep;72(3):1089–1092. [PubMed] [Google Scholar]
  9. Kinoshita T., Medof M. E., Nussenzweig V. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes. J Immunol. 1986 May 1;136(9):3390–3395. [PubMed] [Google Scholar]
  10. Lachmann P. J., Bowyer D. E., Nicol P., Dawson R. M., Munn E. A. Studies on the terminal stages of complement lysis. Immunology. 1973 Jan;24(1):135–145. [PMC free article] [PubMed] [Google Scholar]
  11. Lachmann P. J., Thompson R. A. Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med. 1970 Apr 1;131(4):643–657. doi: 10.1084/jem.131.4.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  13. Lumsden C. E. The immunogenesis of the multiple sclerosis plaque. Brain Res. 1971 May 21;28(3):365–390. doi: 10.1016/0006-8993(71)90052-7. [DOI] [PubMed] [Google Scholar]
  14. McCarthy K. D., de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980 Jun;85(3):890–902. doi: 10.1083/jcb.85.3.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Medof M. E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984 Nov 1;160(5):1558–1578. doi: 10.1084/jem.160.5.1558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Meri S., Morgan B. P., Davies A., Daniels R. H., Olavesen M. G., Waldmann H., Lachmann P. J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990 Sep;71(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  17. Okada N., Harada R., Fujita T., Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol. 1989;1(2):205–208. doi: 10.1093/intimm/1.2.205. [DOI] [PubMed] [Google Scholar]
  18. Raff M. C., Miller R. H., Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature. 1983 Jun 2;303(5916):390–396. doi: 10.1038/303390a0. [DOI] [PubMed] [Google Scholar]
  19. Rollins S. A., Sims P. J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990 May 1;144(9):3478–3483. [PubMed] [Google Scholar]
  20. Rollins S. A., Zhao J., Ninomiya H., Sims P. J. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol. 1991 Apr 1;146(7):2345–2351. [PubMed] [Google Scholar]
  21. Scolding N. J., Morgan B. P., Houston A., Campbell A. K., Linington C., Compston D. A. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies. J Neurol Sci. 1989 Feb;89(2-3):289–300. doi: 10.1016/0022-510x(89)90030-0. [DOI] [PubMed] [Google Scholar]
  22. Seya T., Atkinson J. P. Functional properties of membrane cofactor protein of complement. Biochem J. 1989 Dec 1;264(2):581–588. doi: 10.1042/bj2640581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sims P. J., Rollins S. A., Wiedmer T. Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J Biol Chem. 1989 Nov 15;264(32):19228–19235. [PubMed] [Google Scholar]
  24. Vanguri P., Koski C. L., Silverman B., Shin M. L. Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc Natl Acad Sci U S A. 1982 May;79(10):3290–3294. doi: 10.1073/pnas.79.10.3290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Vanguri P., Shin M. L. Activation of complement by myelin: identification of C1-binding proteins of human myelin from central nervous tissue. J Neurochem. 1986 May;46(5):1535–1541. doi: 10.1111/j.1471-4159.1986.tb01773.x. [DOI] [PubMed] [Google Scholar]
  26. Whitlow M. B., Iida K., Stefanova I., Bernard A., Nussenzweig V. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol. 1990 Mar;126(1):176–184. doi: 10.1016/0008-8749(90)90310-n. [DOI] [PubMed] [Google Scholar]
  27. Wren D. R., Noble M. Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody. Proc Natl Acad Sci U S A. 1989 Nov;86(22):9025–9029. doi: 10.1073/pnas.86.22.9025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zajicek J., Wing M. G., Lachmann P. J., Compston D. A. Mechanisms of oligodendrocyte interaction with normal human serum--defining the role of complement. J Neurol Sci. 1992 Mar;108(1):65–72. doi: 10.1016/0022-510x(92)90189-r. [DOI] [PubMed] [Google Scholar]
  29. Zalman L. S., Wood L. M., Müller-Eberhard H. J. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975–6979. doi: 10.1073/pnas.83.18.6975. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES